Abstract
The purpose of this study is to evaluate the safety and tolerability of MEDI8897 compared to
palivizumab when administered to preterm infants entering their first RSV season and children
with chronic lung disease (CLD) and congenital heart disease (CHD) entering their first and
second RSV season.
